Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Incyte Corporation